What’s New in Pancreatic Cancer? Early Data from the TWINPEAK Bispecific Antibody Study Join GI oncology experts Dr. Anwaar Saeed (University of Pittsburgh), Dr. Zev Wainberg (UCLA), and Dr. Teresa Macarulla (Vall d’Hebron Institute of Oncology, Spain) as they discuss early findings from the TWINPEAK trial, presented at American Society of Clinical Oncology GI 2026 in San Francisco. ✅ Early efficacy and safety data of Spevatamig, a first-in-class bispecific T-cell engager targeting Claudin 18.2

Hershey Medical Center attacks cancer with MRI-guided radiation therapy

Emily Whitehead, First Pediatric Patient to Receive CAR T-Cell Therapy, Celebrates Cure 10 Years Later